Clinical and microbiological characteristics of purulent and non-purulent cellulitis in hospitalized Taiwanese adults in the era of community-associated methicillin-resistant Staphylococcus aureus

Chun-Yuan Lee¹, Hung-Chin Tsai¹, Calvin M. Kunin³, Susan Shin-Jung Lee¹,² and Yao-Shen Chen¹,²,⁴*

Abstract

Background: The risk factors, microbial etiology, differentiation, and clinical features of purulent and non-purulent cellulitis are not well defined in Taiwan.

Methods: We conducted a retrospective cohort study of hospitalized adults with cellulitis in Taiwan in 2013. The demographic characteristics, underlying diseases, clinical manifestations, laboratory and microbiological findings, treatments, and outcomes were compared for patients with purulent and non-purulent cellulitis.

Results: Of the 465 patients, 369 had non-purulent cellulitis and 96 had purulent cellulitis. The non-purulent group was significantly older (p = 0.001) and was more likely to have lower limb involvement (p < 0.001), tinea pedis (p = 0.003), stasis dermatitis (p = 0.025), a higher Charlson comorbidity score (p = 0.03), and recurrence at 6 months post-infection (p = 0.001) than the purulent group. The purulent group was more likely to have a wound (p < 0.001) and a longer hospital stay (p = 0.001) and duration of antimicrobial therapy (p = 0.003) than the non-purulent group. The etiological agent was identified in 35.5 % of the non-purulent cases, with β-hemolytic streptococci the most frequent cause (70.2 %). The etiological agent was identified in 83.3 % of the purulent cases, with Staphylococcus aureus the predominant pathogen (60 %). 50 % of these were methicillin-resistant S. aureus (MRSA). In multivariable analysis, purulent group (odds ratio (OR), 5.188; 95 % confidence interval (CI), 1.995–13.493; p = 0.001) was a positive predictor of MRSA. The prescribed antimicrobial agents were significantly different between the purulent and non-purulent groups, with penicillin the most frequently used antimicrobial agent in the non-purulent group (35.2 %), and oxacillin the most frequent in the purulent group (39.6 %). The appropriate antimicrobial agent was more frequently prescribed in the non-purulent group than in the purulent group (83.2 % vs. 53.8 %, p < 0.001).

Conclusions: The epidemiology, clinical features, and microbiology of purulent and non-purulent cellulitis were significantly different in hospitalized Taiwanese adults. Purulence was a positive predictor of MRSA as the causal agent of cellulitis. These findings provide added support for the adoption of the IDSA guidelines for empirical antimicrobial therapy of cellulitis in Taiwan.

Keywords: Cellulitis, Methicillin-resistant Staphylococcus aureus, Soft tissue infections, Staphylococcal skin infections
Background

Cellulitis is a diffuse, spreading infection that involves the dermis and subcutaneous tissues of the skin. Predisposing factors include prior trauma (e.g., abrasion, laceration, puncture wounds), tinea pedis, stasis dermatitis, compromised lymphatic drainage, and venous insufficiency. It is often difficult to make a microbiological diagnosis because of the low recovery rate from needle aspirates, skin biopsies, and blood cultures [1, 2], and because of the identification of widely different causative organisms depending on the diagnostic tests used [3–5].

A confounding factor is the emergence of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). Until the mid-1990s, MRSA infections were limited to hospitals. However, within the last decade, MRSA outbreaks have been seen in healthy individuals without connection to healthcare institutions [6]. CA-MRSA differs from healthcare-associated MRSA (HA-MRSA) in several ways, including a more limited antibiotic resistance profile, exotoxin gene profile (Panton Valentine leukocidin), type of staphylococcal cassette chromosome mec (SCCmec) gene, and clinical spectrum [7–9]. Infections of the skin and soft tissues account for 72–86% of CA-MRSA cases [7, 8, 10]. The clinical manifestations range from mild skin and soft tissue infections, cutaneous abscesses, and purulent cellulitis [11, 12], to severe, life-threatening infections, including pyomyositis and myositis [13]. CA-MRSA is now the most important pathogen in purulent skin and soft tissue infections in the United States and Asia [11, 14].

The 2011 Infectious Diseases Society of America (IDSA) guidelines for the management of MRSA emphasize the need to distinguish purulent from non-purulent infections to clarify the relative contributions of β-hemolytic streptococci and S. aureus and their implications for antimicrobial therapy [15]. The epidemiology, microbiology, clinical manifestations, and contribution of CA-MRSA to non-purulent and purulent cellulitis are not well defined in Taiwan. In Taiwan, initial therapy for cellulitis is often empirical, using broad-spectrum coverage without adequate distinction between the microbiological etiology of non-purulent and purulent cellulitis.

This 1-year retrospective cohort study, conducted at Kaohsiung Veterans General Hospital in Southern Taiwan, was initiated to better understand the epidemiology, clinical features, and microbiology of non-purulent and purulent cellulitis in hospitalized Taiwanese adults. The findings are to be used as a basis for the development of guidelines for the diagnosis and management of cellulitis in Taiwan.

Methods

Study design

We conducted a 1-year retrospective cohort study, from January to December 2013, of the medical records of all adult patients admitted with the diagnosis of cellulitis to the Kaohsiung Veterans’ General Hospital (KVGH). KVGH is a 1200-bed general and tertiary care hospital located in Southern Taiwan. In our initial investigation, chart review of cases with International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) codes of 729.4 (fasciitis), 728.86 (necrotizing fasciitis), and 608.83 (Fournier’s gangrene) were also carried out. Although some cases were initially diagnosed as cellulitis because of spreading erythema and swelling, these were finally diagnosed as deeper skin and soft tissue infections, and were not included in our study. The inclusion criteria were based on ICD-9-CM codes 528.3, 608.4, 681.00–681.9, and 682.0–682.9. Patients aged ≤20 years or those found not to have cellulitis on chart review were excluded from the study. The cases that met the inclusion criteria were further divided into non-purulent and purulent groups according to the definitions provided below. The two groups were then compared for demographic characteristics, underlying diseases, clinical manifestations, laboratory findings, diagnostic methods, pathogen, and outcomes. The study was approved by the ethical committee of Kaohsiung Veterans General Hospital (VGHKS14-CT12-01).

Data collection

Hospital records were retrieved and relevant epidemiological, clinical, and microbiological data were compiled. Outcomes included length of hospital stay, antimicrobial therapy, 30-day all-cause and cellulitis-related mortality, and recurrent episodes of cellulitis at the initial site at 6 months post-infection.

Definitions

Wound is defined as a pre-existing skin lesion at the time of skin infection onset, such as a chronic ulcer, or a trauma-related skin lesion, such as lacerations, abrasions, or punctures. Surgical site infection is not included in the present study.

Purulent cellulitis was initially defined as skin lesions associated with purulent drainage or exudate in the absence of a drainable abscess [15]. A cutaneous abscess was defined as a collection of pus within the dermis and deeper skin tissues [16]. Because of the difficulties associated with differentiating purulent cellulitis from cutaneous abscess in a retrospective chart review, we combined these two presentations into the purulent group. Non-purulent cellulitis was defined as cellulitis without purulent drainage or exudate or associated abscess [15].

CA-MRSA was defined as MRSA isolated from a patient who had none of the following established risk factors for HA-MRSA. These included isolation of MRSA > 48 h after hospital admission, history of prior hospitalization, surgery, dialysis, or residence in a long-term care facility...
within the previous year, the presence of an indwelling urinary catheter or a percutaneous device at the time of culture, or previous isolation of MRSA [17, 18]. Modified case definition, which excludes the previous isolation of MRSA as a criterion for HA-MR, was also analyzed in the present study [19].

An appropriate antimicrobial agent was defined as an antimicrobial agent to which the identified pathogen was susceptible.

Recurrence of cellulitis was defined as an attack of cellulitis in the same anatomical site within 6 months of cure of the previous episode of cellulitis.

**Microbiological studies**

Bacteria were identified and antimicrobial susceptibility profiles were determined using a Vitek two automated system (bioMérieux, Canada) at the KVGH Clinical Microbiology Laboratory. All *S. aureus* isolates susceptible to oxacillin underwent confirmatory disk diffusion testing for cefoxitin susceptibility. MRSA isolates were tested for susceptibility to erythromycin, clindamycin, levofloxacin, rifampin, trimethoprim-sulfamethoxazole, and vancomycin. The D-test was performed to detect inducible clindamycin resistance for isolates that were resistant to erythromycin, but susceptible to clindamycin. All tests were performed and interpreted in accordance with Clinical and Laboratory Standards Institute guidelines (M100-S19).

Blood and pus cultures, skin biopsy, and serological antistreptolysin O titer (ASOT) reports were collected and analyzed. Coagulase-negative staphylococci, diphtheroids, and *Bacillus* species were considered to be blood culture contaminants when isolated from one culture bottle of a set, or when another set of blood culture bottles was sterile. A positive wound culture was defined as isolation of a bacterium from both a superficial and a deep site. The term β-hemolytic streptococci was used rather than *Streptococcus pyogenes* because the isolates were not differentiated by group. When both acute and convalescent ASOT results were not available to demonstrate a ≥2-fold increase in titer, a single positive ASOT with a titer of ≥200 U/mL, according to the manufacturer, was considered to be positive.

**Statistical analysis**

All statistical analyses were performed using SPSS version 12.0 (SPSS, Chicago, IL, USA). Descriptive statistics were used to summarize the characteristics of the patients and the relative contributions of the non-purulent and purulent groups. Categorical variables were compared between these two groups using the χ² or Fisher’s exact tests, and continuous variables were compared using an independent *t*-test. All tests were 2-tailed, and *p* < 0.05 was considered significant. Multivariable analyses of predictive factors for MRSA were performed in patients with a final pathogen diagnosis using the LOGISTIC procedure, and the candidate variables were identified as those having a univariate significance of *p* ≤ 0.10, those identified in a previous study, or those believed to be clinically meaningful.

**Results**

**Demographic characteristics and underlying diseases in patients with cellulitis**

We reviewed the medical records of 968 patients initially identified as having cellulitis. We excluded 503 cases (52.0 %) for the following reasons: infections other than cellulitis (382; 75.9 %), age ≤20 years (85; 16.9 %), non-infectious diseases (33; 6.6 %), and incomplete records (3; 0.6 %). The study population consisted of the remaining 465 patients, of which 369 (79.4 %) had non-purulent and 96 (20.6 %) had purulent cellulitis. Their demographic characteristics and underlying diseases are summarized in Table 1. The median age was 62 years (range, 20–96 years; SD ± 20.2); 61.3 % were men. The non-purulent group was significantly older (64 vs. 56 years, *p* = 0.001) and more likely to have tinea pedis (18.7 % vs. 6.3 %, *p* = 0.003), stasis dermatitis (7.0 % vs. 1.0 %, *p* = 0.025), and a higher Charlson comorbidity score (1.5 vs. 1.1, *p* = 0.03) than the purulent group. The purulent group was more likely to have a wound (44.9 % vs. 22.8 %, *p* < 0.001) than the non-purulent group. There were no significant differences between the two groups in gender composition.

**Clinical and laboratory manifestations of patients with cellulitis**

The clinical and laboratory findings for the 465 cases of cellulitis are summarized in Table 2. There were no significant differences between the two groups in frequency of sepsis at admission or clinical laboratory findings. Cellulitis was localized to the lower extremities, upper extremities, and head and neck in 78.7, 8.6, and 7.5 % of cases, respectively. Although lower extremity cellulitis was the most common site of infection in both groups, it was significantly more frequent in the non-purulent than the purulent group (82.4 % vs. 62.5 %, *p* < 0.001).

**Microbiological and serological studies**

Microbiological and/or serological studies were performed in 91.6 % of cases in the non-purulent group and in 97.9 % of cases in the purulent group (Table 3). Wound culture, blood culture, ASOT, and skin biopsy were performed in 33.3, 75.5, 45.2, and 0.2 % of cases, respectively. One or more bacterial species were isolated from 110 of the 155 (71.0 %) wound cultures. Of the 110 patients with a positive wound culture, 15 (13.6 %) had superficial and 95 (86.4 %) had deep wounds. The prevalence of positive wound culture was higher in the
purulent group than in the non-purulent group (88.6 % vs. 47.8 %, \( p < 0.001 \)). Thirty-three of the 351 blood cultures (9.4 %) met the criterion for a positive culture. There was no significant difference in the prevalence of positive blood cultures between the non-purulent and purulent groups (8.2 % vs. 15.0 %, \( p = 0.103 \)). Of the 210 patients with measured ASOT, paired acute and convalescent ASOT was collected in 18 non-purulent cases, but no purulent cases. A positive ASOT as defined above was noted in 84 of the 210 patients (40.0 %). The ASOT-positive rate was higher in the non-purulent than the purulent group (42.8 % vs. 11.1 %, \( p = 0.03 \)).

### Table 1: Demographic characteristics and underlying diseases among 465 cellulitis cases

|                          | All (n = 465) | Non-purulent group (n = 369) | Purulent group (n = 96) | \( P \)-value |
|--------------------------|--------------|-----------------------------|------------------------|-------------|
| Age (years), mean (SD)   | 62 (20.2)    | 64 (19.4)                   | 56 (21.9)              | 0.001       |
| Male sex, no. (%)        | 285 (61.3)   | 221 (59.9)                  | 64 (66.7)              | 0.225       |
| Wound (%)                | 123 (26.5)   | 84 (22.8)                   | 39 (40.9)              | <0.001      |
| Charlson comorbidity score, mean (SD) | 1.4 (1.6)    | 1.5 (1.6)                   | 1.1 (1.5)              | 0.03        |
| Diabetes mellitus (%)    | 119 (25.9)   | 101 (27.4)                  | 18 (18.8)              | 0.085       |
| Autoimmune disease (%)   | 16 (3.4)     | 13 (3.5)                    | 3 (3.1)                | 1.00        |
| Solid malignancy (%)     | 65 (14)      | 56 (15.2)                   | 9 (9.4)                | 0.144       |
| Hematological malignancy (%) | 13 (2.8)     | 12 (3.3)                    | 1 (1.0)                | 0.484       |
| Liver cirrhosis (%)      | 29 (6.2)     | 20 (5.4)                    | 9 (9.4)                | 0.153       |
| HIV infection (%)        | 4 (0.9)      | 3 (0.8)                     | 1 (1.0)                | 1.00        |
| Organ transplantation (%)| 2 (0.4)      | 2 (0.5)                     | 0 (0.0)                | 1.00        |
| Chronic obstructive pulmonary disease (%) | 13 (2.8)    | 9 (2.4)                     | 4 (4.2)                | 0.318       |
| Peripheral artery occlusive disease (%) | 18 (3.9)  | 14 (3.8)                    | 4 (4.2)                | 0.773       |
| Coronary artery bypass graft (%) | 11 (2.4) | 9 (2.4)                     | 2 (2.1)                | 1.00        |
| Fracture (%)             | 9 (1.9)      | 9 (2.4)                     | 0 (0.0)                | 0.215       |
| Flap (%)                 | 9 (1.9)      | 9 (2.4)                     | 0 (0.0)                | 0.215       |
| Lymph node dissection (%)| 21 (4.5)     | 19 (5.1)                    | 2 (2.1)                | 0.273       |
| Tinea pedis (%)          | 75 (18.1)    | 69 (18.7)                   | 6 (6.3)                | 0.003       |
| Stasis dermatitis (%)    | 27 (5.8)     | 26 (7.0)                    | 1 (1.0)                | 0.025       |

Data are no. (% of patients, unless otherwise indicated.

### Table 2: Clinical manifestations, laboratory findings, and outcomes among 465 cellulitis cases

|                          | All (n = 465) | Non-purulent group (n = 369) | Purulent group (n = 96) | \( P \)-value |
|--------------------------|--------------|-----------------------------|------------------------|-------------|
| Lower extremities involved (%) | 364 (78.3) | 304 (82.4)                  | 60 (62.5)              | <0.001      |
| Sepsis at admission (%)  | 127 (27.3)   | 103 (27.9)                  | 24 (25.0)              | 0.568       |
| WBC, mean 10^9/L (SD)     | 10.3 (4.9)   | 10.2 (5.0)                  | 10.5 (4.8)             | 0.572       |
| Hb (g/dL), mean (SD)      | 12.9 (2.2)   | 12.9 (2.2)                  | 13.0 (2.3)             | 0.658       |
| PLT/mm^3 (SD)             | 200.6 (78.9) | 195.0 (77.2)                | 221.9 (82)             | 0.003       |
| Lactic acid (mmol/L), mean (SD) | 1.8 (1.2)  | 1.8 (1.2)                   | 1.9 (1.3)              | 0.917       |
| Cr (mg/dL), mean (SD)     | 1.3 (1.7)    | 1.4 (1.9)                   | 1.1 (0.7)              | 0.175       |
| CK (U/L), mean (SD)       | 142.1 (343)  | 144.2 (368)                 | 131.8 (165.9)          | 0.813       |
| CRP (mg/dL), mean (SD)    | 6.3 (7.6)    | 6.3 (7.7)                   | 6.3 (7.4)              | 0.993       |
| GOT (IU/L), mean (range)  | 31.0 (23.6)  | 30.4 (19.8)                 | 33.2 (34.4)            | 0.5         |
| Albumin (g/dL), mean (SD) | 3.1 (0.7)    | 3.1 (0.7)                   | 3.2 (0.6)              | 0.71        |
| Recurrence within 6 months (%) | 57 (12.3) | 54 (14.6)                   | 3 (3.1)                | 0.001       |
| Death within 30 days (%)  | 3 (0.6)      | 3 (0.8)                     | 0 (0)                  | 1.0         |
| Length of stay, days (SD) | 9 (6.5)     | 8 (5.8)                     | 11 (8.1)               | 0.001       |
| Duration of antimicrobial therapy, days (SD) | 14 (9.7) | 13 (9)                     | 17 (12)                | 0.003       |

Data are number (% of patients, unless otherwise indicated.

CK creatine kinase, Cr creatinine, CRP C-reactive protein, GOT glutamate oxaloacetate transaminase, Hb hemoglobin, PLT platelet count, SD standard deviation
Microbiological findings
The etiological agent(s) were identified from one or more sites or by serology in 211 of the 465 patients (45.4 %) (Table 4). The causative bacteria were identified in 35.5 % of the non-purulent cases and 83.3 % of the purulent group. β-hemolytic streptococci were the predominant bacterial pathogens among patients with non-purulent cellulitis with positive microbiological findings, accounting for 70.2 % of cases (92/131). β-hemolytic streptococci were identified by wound culture (three cases, 3.3 %), ASOT (76 cases, 82.6 %), blood culture (seven cases, 7.6 %), or ASOT and blood culture (six cases, 6.5 %). The next most frequently identified bacteria in the non-purulent group were S. aureus (12.2 %), Gram-negative bacilli (9.9 %), and polymicrobial pathogens (4.6 %). S. aureus was the most common pathogen (60.0 %) amongst the 80 patients in the purulent group with positive microbiological findings, followed by polymicrobial pathogens (18.8 %), Gram-negative bacilli (12.5 %), and β-hemolytic streptococci (5.0 %). MRSA were more frequently isolated from the purulent than the non-purulent group (30.0 % vs. 6.1 %, p < 0.001). CA-MRSA, defined by both epidemiological criteria [17–19] reported the same number of cases, and were isolated in 21.3 % of cases in the purulent group and 3.8 % of cases in the non-purulent group (p = 0.681).

Antimicrobial susceptibility of MRSA stratified by CA-MRSA criteria
The antimicrobial susceptibility profiles of the 32 MRSA isolates were shown in Table 5. There was no significant difference in antimicrobial susceptibility between CA-MRSA and non-CA-MRSA isolates.

Multivariable analyses of predictive factors for MRSA infection in 211 cases with a final pathogen diagnosis
Following adjustment for age, sex, sepsis, lower limb involvement, history of tinea pedis, diabetes, and wound, purulence was a positive predictor of MRSA infection (odds ratio (OR), 5.188; 95 % confidence interval (CI), 1.995–13.493; p = 0.001) (Table 6).
Empirical prescription of antimicrobial agents

The empirical prescription of antimicrobial agents is detailed in Table 7. In this study, the five most commonly prescribed antimicrobial agents were penicillin (29.5 %), oxacillin (28.6 %), cefazolin (19.4 %), β-lactam/β-lactamase inhibitors (3.7 %), and penicillin plus clindamycin (3.4 %). The prescription of antimicrobial agents differed significantly between the purulent and non-purulent groups. Penicillin was the most frequently prescribed agent in the non-purulent group (35.2 %), whereas oxacillin was the most frequently prescribed agent in the purulent group (39.6 %). The appropriate antimicrobial agent was more frequently prescribed in the non-purulent group than in the purulent group (83.2 % vs. 53.8 % of cases, \( p < 0.001 \)). Among the 32 cases of MRSA identified, 12.5 % (4/32) of cases received the appropriate antibiotic therapy, and the prevalence of appropriate antimicrobial agent use was not significantly different between the purulent and non-purulent groups (16.7 % vs. 0 %, \( p = 0.55 \)).

Outcomes

The length of hospital stay and duration of antimicrobial therapy were shorter for the non-purulent group compared with the purulent group (8 vs. 11 days, \( p = 0.001 \); 13 vs. 17 days, \( p = 0.003 \), respectively). More patients underwent surgery in the purulent group than in the non-purulent group (49 % vs. 4.1 %, \( p < 0.001 \)), and recurrence within 6 months post-infection was higher in the non-purulent group than in the purulent group (14.6 % vs. 3.1 %, \( p = 0.001 \)). Three of the 465 patients (0.6 %) died within 6 months of discharge. None of the deaths were attributable to cellulitis.

Discussion

The risk factors and the clinical and microbiological features of purulent and non-purulent cellulitis among hospitalized Taiwanese adults in the current study were remarkably similar to those reported in Western countries [20–24]. In the present study, patients with non-purulent cellulitis were more likely to have lower limb involvement, stasis dermatitis, and tinea pedis, along with a higher likelihood of recurrence than those with purulent cellulitis. As in other studies, β-hemolytic streptococci were the predominant pathogens in the non-purulent group [2, 25], and S. aureus was the most common pathogen in the purulent group [11].

Cellulitis is a relatively common infectious disease in both children and adults. To ensure proper treatment, it needs to be differentiated from focal infections with surrounding inflammation, such as septic bursitis, osteomyelitis and septic arthritis, and non-infectious inflammatory diseases. We excluded 503 of the original 968 patients (52.0 %) because of misdiagnoses. The three most common misdiagnosed
infections were anorectal abscesses \( (n = 84) \), deep layer involvement \( (n = 64) \), and odontogenic infection \( (n = 37) \). The three most common misdiagnosed non-infectious diseases were phlebitis \( (n = 42) \), deep vein thrombosis \( (n = 7) \), and tumor with central necrosis \( (n = 5) \).

A large study conducted in emergency departments across the United States demonstrated that 76 % of cases of purulent soft tissue infection were caused by *S. aureus*, 59 % of which were CA-MRSA \[11\]. The present study demonstrates similar results. Of the purulent cases in which the etiological agent was identified, 60 % were caused by *S. aureus*, 35.4 % of which were CA-MRSA. A prospective study of 179 patients with non-purulent cellulitis based on acute and convalescent sera for ASO and DNase-B antibodies found that 73 % of cases had serological evidence of β-hemolytic *Streptococcus* infection \[2\]. A recently published prospective study of 77 cases with non-necrotizing cellulitis using serological study of *Streptococcus* also demonstrated similar results \[25\]. In the present study, however, the serological evidence of streptococcus infection may be underestimated in the non-purulent group because paired acute and convalescent ASOT were collected in only 18 cases, 66.7 % \( (12/18) \) of which were positive. 90.6 % \( (174/192) \) cases with measured ASOT in the non-purulent group received only a single ASOT, and the prevalence of positive ASOT was 40.2 % \( (70/174) \).

An increased ASOT between the acute and convalescent phases provides a more accurate reflection of a preceding streptococcal infection than a single titer \[26\]. However, it is not always feasible to obtain paired sera. Therefore, the occurrence of a single isolated titer that is higher than the upper limit of normal value is also evidence of a previous streptococcal infection. In patients with group A streptococcal infections, ASOT begins to rise after approximately 1 week, reaching maximal levels at 3–6 weeks post-infection \[27, 28\], and begins to decline in uncomplicated infections at 6–8 weeks post-infection, although in some patients the titer may remain elevated for indefinite periods \[29\]. We reviewed the charts of the 70 non-purulent cases with a single positive ASOT in the current study, which showed that only six of these cases experienced another episode of cellulitis in the year preceding the current episode. These findings provide further support for β-hemolytic streptococci being the causative organism in the majority of the 70 cases with a single positive ASOT.

The lower rate of ASOT performed in the purulent group compared with the non-purulent group may have led to an underestimation of the incidence of *Streptococcus* infection (purulent vs. non-purulent, 18.8 % vs. 52.0 %, \( p <0.001 \)). This selection bias is unavoidable in a retrospective study, but may be limited. First, the lower rate of ASOT testing in the purulent group may reflect the fact that these patients did not present with typical *Streptococcus* cellulitis, which is characterized by rapidly spreading areas of inflammation in the lower extremities, sometimes accompanied by lymphangitis and regional lymphadenitis in cases with predisposing conditions, such as tinea pedis, stasis dermatitis, compromised lymphatic drainage, and venous insufficiency. Second, the prevalence of positive ASOT, whether as single or paired results, was significantly lower in the purulent group than in the non-purulent group (purulent vs. non-purulent, 11.1 % vs. 42.75 %, \( p =0.031 \)).

In the present study, cellulitis cases were treated by a range of practitioners, including primary care, emergency, and other specialist physicians. Multiple antibiotics were empirically prescribed for cellulitis, and these differed significantly between the non-purulent and purulent groups (Table 7). The rate of prescription of inappropriate antimicrobial agents was higher in the purulent group than in the non-purulent group (46.2 % vs. 16.8 %, \( p <0.001 \)). Overuse of antibiotics is associated with increased antibiotic resistance and cost of treatment \[30, 31\]. However, inappropriately withholding

### Table 7 Empirical prescription of antimicrobial agents. A. All cases of cellulitis B. Cases with pathogen isolated

| A. Prescription of antimicrobial agents in all 465 cases of cellulitis | All \( (n = 465) \) | Non-purulent group \( (n = 369) \) | Purulent group \( (n = 96) \) | \( P \)-value |
|---|---|---|---|---|
| Penicillin (%) | 137 (29.5) | 130 (35.2) | 7 (7.3) | <0.001 |
| Oxacillin (%) | 133 (28.6) | 95 (25.7) | 38 (39.6) | 0.008 |
| Cefazolin (%) | 90 (19.4) | 73 (19.8) | 17 (17.7) | 0.647 |
| \( β \)-lactam/\( β \)-lactamase inhibitor (%) | 17 (3.7) | 9 (2.4) | 8 (8.3) | 0.012 |
| Penicillin plus clindamycin (%) | 16 (3.4) | 16 (4.3) | 0 (0.0) | 0.052 |
| Other (%) | 72 (15.4) | 46 (12.5) | 26 (27.1) | <0.001 |

| B. Prevalence of appropriate antimicrobial agent in 211 cases with pathogen isolated | All \( (n = 211) \) | Non-purulent group \( (n = 131) \) | Purulent group \( (n = 80) \) | \( P \)-value |
|---|---|---|---|---|
| Appropriate antimicrobial agent (%) | 152 (72.0) | 109 (83.2) | 43 (53.8) | <0.001 |

Data are number (%) of patients, unless otherwise indicated.
necessary antibiotics may have adverse effects on outcomes. The impact of inappropriate antimicrobial agent use on length of hospital stay, duration of antimicrobial therapy and medical cost needs further analysis.

There has been much discussion as to whether coverage for CA-MRSA should be included in empirical regimens for cellulitis. Published guidelines offer different recommendations. The 2011 IDSA guidelines for MRSA management recommend antimicrobial therapy targeting β-hemolytic streptococci for non-purulent cellulitis, and specific CA-MRSA therapy for cases of purulent cellulitis [15]. The 2014 IDSA guidelines for skin and soft tissue infection management recommend antimicrobial therapy effective against both MRSA and streptococci for patients whose cellulitis is associated with penetrating trauma, evidence of MRSA infection elsewhere, nasal colonization with MRSA, injection drug use, or systemic inflammatory response syndrome [16]. However, there are several issues that need to be addressed to provide an optimal approach for the use of antibiotics in the management of cellulitis. The diagnosis and management of cellulitis depend largely on clinical features. Clinicians are often unwilling to pursue microbiological diagnosis because of the absence of culturable material in most cases of non-purulent cellulitis, the relatively low recovery rate of pathogens [1], and favorable prognosis in most cases following empirical therapy. Some primary physicians may use a strategy known as double coverage, which refers to the use of at least two antibiotics with Gram-positive coverage (such as trimethoprim-sulfamethoxazole plus cephalaxin) to target MRSA, methicillin-sensitive S. aureus, and β-hemolytic streptococci [32]. However, a recent randomized, multicenter, double-blinded, placebo-controlled trial demonstrated no improvement in outcomes among patients with uncomplicated (non-purulent) cellulitis treated with trimethoprim-sulfamethoxazole in addition to cephalaxin compared with those treated with cephalaxin alone [33].

In the current study, MRSA was more frequently isolated from the purulent group than the non-purulent group (MRSA: 30.0 % vs. 6.1 %, p < 0.001). In multivariable analyses of factors that could be used for prediction of MRSA infection, only purulence was a positive predictor of MRSA (OR, 5.188; 95 % CI, 1.995–13.493; p = 0.001). The lack of a significant difference in prevalence of CA-MRSA between the two groups may be caused by the small number of isolates (CA-MRSA: purulent vs. non-purulent: 21.3 % vs. 3.8 %, p = 0.681). Initial empirical antimicrobial therapy, when prescribed, must be chosen based on local antimicrobial sensitivity data. ST59-MRSA-VT/IV is the predominant CA-MRSA clone in Taiwan [34, 35]. This clone is typically resistant to erythromycin, clindamycin, and occasionally, gentamicin, but is susceptible to trimethoprim-sulfamethoxazole, tetracyclines, and fluoroquinolones [34]. Because of the retrospective nature of the present study, we were unable to access the bacterial isolates for molecular epidemiological studies. However, the antimicrobial sensitivity testing of the 22 CA-MRSA isolates provided similar results.

The current study provides strong support for the clinical approach recommended in the 2011 IDSA guidelines, dividing cellulitis into purulent and non-purulent groups to help select the appropriate empirical antimicrobial therapy to be applied in Taiwan. This consists of β-lactam agents directed at streptococci for non-purulent cellulitis, and antibiotics active against MRSA for purulent cellulitis.

The major limitation of this study is information bias, which is inherent in all retrospective studies. It also unavoidably contributes to selection bias because not all patients received paired ASOT testing, and none of the patients underwent a serological test for S. aureus. Both of these factors may lead to an underestimate of the role of β-hemolytic streptococci and S. aureus as etiological agents of cellulitis. Additionally, our inability to differentiate cutaneous abscess from purulent cellulitis may have overestimated the number of cases in the purulent group. The current study also only examined patients from one hospital over a 1-year period. A multicenter-study is needed to generalize our findings to all of Taiwan. Prospective studies are needed to assess changes that might occur regarding the predominant microorganisms, and the emergence of antibiotic-resistant bacteria. Finally, the patients in this study were limited to hospitalized cases, meaning that infections were more severe. Therefore, the results of this study cannot be generalized to all patients with cellulitis in Taiwan.

Conclusions

In conclusion, the epidemiology, clinical features, and microbiology of purulent and non-purulent cellulitis were significantly different in hospitalized Taiwanese adults. Understanding the local epidemiology and etiological agents is essential for the development of guidelines for empirical antimicrobial therapy of cellulitis in Taiwan and other countries in South East Asia.

Abbreviations

ASOT: Antistreptolysin O titer; CA-MRSA: Community-associated methicillin-resistant Staphylococcus aureus; CK: Creatine kinase; Cr: Creatinine; CRP: C-reactive protein; GOT: Glutamate oxaloacetate transaminase; HA-MRSA: Healthcare-associated methicillin-resistant Staphylococcus aureus; Hb: Hemoglobin; ICD-9-CM: International Classification of Disease, Ninth Revision, Clinical Modification; IDSA: Infectious Diseases Society of America; PLT: Platelet count; SCCmec: Staphylococcal cassette chromosome mec; SD: Standard deviation.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

C-YL conceived and designed the study and drafted the manuscript. H-CT, CMK, and SS-JL conceived and designed the study, and analyzed and
interpreted the data. Y-SC critically revised the manuscript. All authors read and approved the final manuscript.

Acknowledgements
The authors thank Dr. ChiHChen Chou for her assistance with drafting the manuscript.

Author details
1Division of Infectious Diseases, Department of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. 2Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan. 3Department of Internal Medicine (CMK), Ohio State University, Columbus, Ohio and the University of Arizona, Tucson, Arizona, USA. 4Graduate Institute of Science Education and Environmental Education, National Kaohsiung Normal University, Kaohsiung, Taiwan. 5University of Arizona, Tucson, AZ, USA.

Received: 25 March 2015 Accepted: 28 July 2015
Published online: 05 August 2015

References
1. Hooten TM, Horton CA, Coyle MB, Ramsey PG, Turek M. Microbiologic evaluation of cutaneous cellulositis in adults. Arch Intern Med. 1986;146:295–7.
2. Jeng A, Beheisti M, Li J, Nathan R. The role of beta-hemolytic streptococci in causing diffuse, nonculturable cellulitis: a prospective investigation. Medicine (Baltimore). 2010;89:217–26.
3. Gunderson CG, Martinello RA. A systematic review of bacteremias in cellulitis and erysipelas. J Infect. 2012;64:148–55.
4. Chis A, Miller L. Staphylococcus aureus: the most common identified cause of cellulitis: a systematic review. Epidemiol Infect. 2010;138:313–7.
5. Jeng A, Beheisti M, Li J, Nathan R. The role of beta-hemolytic streptococci in causing diffuse, nonculturable cellulitis: a prospective investigation. Medicine. 2010;89:217–26.
6. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis. 2007;13:718.
7. Huang Y-C, Chen CJ. Community-associated meticillin-resistant Staphylococcus aureus in children in Taiwan, 2000s. Int J Antimicrob Agents. 2011;38:2–8.
8. Naimi TS, DeLellis RH, Como-Sabetti K, Borchardt SM, Boxrud DJ, Etienne J, et al. Comparison of community- and health care-associated meticillin-resistant Staphylococcus aureus infection. JAMA. 2001;286:2976–84.
9. Fey PD, Said-Salim B, Rupp ME, Hinrichs SH, Boxrud DJ, Davis CC, et al. Comparative molecular analysis of community- or hospital-acquired meticillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2003;47:196–203.
10. Fridkin SK, Hagerman JC, Morrison MA, Sanza LT, Como-Sabetti K, Jernigan JA, et al. Meticillin-resistant Staphylococcus aureus disease in three communities. New Engl J Med. 2005;352:1436–44.
11. Moran BJ, Krishnadath A, Gorwitz RJ, Forshew GE, McDougall LK, Carey RB, et al. Meticillin-resistant S. aureus infections among patients in the emergency department. New Engl J Med. 2006;355:666–74.
12. Ellis MW, Hospenthal DR, Dooley DP, Gray PJ, Munay CK. Natural history of community-acquired meticillin-resistant Staphylococcus aureus colonization and infection in soldiers. Clin Infect Dis. 2004;39:971–9.
13. Pannaraj PS, Hulten KG, Gonzalez BE, Mason Jr EO, Kaplan SL. Infective pyomyositis and myositis in children in the era of community-acquired, meticillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 2006;43:953–60.
14. Chen CJ, Huang YC. New epidemiology of Staphylococcus aureus infection in Asia. Clin Microbiol Infect. 2014;20:605–23.
15. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of meticillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52:825–92.
16. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EI, Gotbakh SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59:e10–52.
17. Morrison M, Hagerman J, Klevens R. Case definition for community-associated meticillin-resistant Staphylococcus aureus. J Hosp Infect. 2006;62:241.
18. Maree CL, Daum RS, Boyle-Vavra S, Matsuyoshi K, Miller LG. Community-associated meticillin-resistant Staphylococcus aureus isolates causing healthcare-associated infections. Emerg Infect Dis. 2007;13:236–42.
19. Klevens RM, Morrison MA, Nadle J, Petit S, Ger Shaman K, Ray S, et al. Invasive meticillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007;298(7):763–71.
20. Horanatson M, Bowman JD. Is community-acquired meticillin-resistant Staphylococcus aureus coverage needed for cellulitis? Infect Dis Ther. 2013;2:175–85.
21. Qualls ML, Mooney MW, Camargo Jr CA, Zuconi T, Hooper DC, Pellan DJ. Emergency department visit rates for abscess versus other skin infections during the emergence of community-associated meticillin-resistant Staphylococcus aureus, 1997–2007. Clin Infect Dis. 2012;55:103–5.
22. Concheiro J, Loureiro M, Gonzalez-Vila D, Garcia-Gavin J, Sanchez-Aguilar D, Toribio J. Erysipelas and cellulitis: a retrospective study of 122 cases. Actas Dermosifiliogr. 2009;100:88–94.
23. Perello-Altamora MR, Santos-Duran JC, Sanchez-Barba M, Canuto J, Marcos M, Unamuno P. Clinical and epidemiological characteristics of adults hospitalized for cellulitis and erysipelas. Eur J Clin Microbiol Infect Dis. 2012;31:2147–52.
24. Lazzarini L, Conti E, Tositti G, de Laat F. Erysipelas and cellulitis: clinical and microbiological spectrum in an Italian tertiary care hospital. J Infect. 2005;51:385–93.
25. Kappelin M, Sliinder T, Haapala A-M, Altoniemi J, Huttunen R, Kere J, et al. Evidence of streptococcal origin of acute non-necrotising cellulitis: a terological study. J Eur J Clin Microbiol Infect Dis. 2013;32:669–72.
26. Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, the American Heart Association. Treatment of acute streptococcal pharyngitis and prevention of rheumatic fever: a statement for health professionals. Pediatrics. 1995;96:758–64.
27. McCarty M. Streptococcal infections. In: McCarty M, editor. The antibody response to streptococcal infections. New York: Columbia University Press; 1954. p. 130–42.
28. Kaplan E, Ferrier P, Wannamaker L. Comparison of the antibody response to streptococcal cellular and extracellular antigens in acute pharyngitis. J Pediatr. 1974;84:21–8.
29. Sheft A, Kaplan EL. Clinical use and interpretation of group A streptococcal antibody tests: a practical approach for the pediatrician or primary care physician. Pediatr Infect Dis J. 2002;21:420–6.
30. May L, Cosgrove S, L’Archequeve M, Talan DA, Payne, P, Jordan J, et al. A call to action for antimicrobial stewardship in the emergency department: approaches and strategies. Ann Emerg Med. 2013;62:69–77. e2.
31. Shehab N, Patel PR, Srinivasan A, Budnitz DS. Emergency department visits for antibiotic-associated adverse events. Clin Infect Dis. 2008;47:735–43.
32. Walraven CJ, Lingenfelter E, Rollo J, Madsen T, Alexander DP. Diagnostic and therapeutic evaluation of community-acquired meticillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infections in the emergency department. J Emerg Med. 2012;42:392–9.
33. Pallin DJ, Binder WD, Allen MB, Lederman M, Parmar S, Fiblin MR, et al. Clinical trial: comparative effectiveness of cephalixin plus trimethoprim-sulphamethoxazole versus cephalaxin alone for treatment of uncomplicated cellulitis: a randomized controlled trial. Clin Infect Dis. 2013;56:1754–62.
34. Wang JT, Liao C-H, Fang C-T, Chie WC, Lai MS, Lauderdale TL, et al. Prevalence of and risk factors for colonization by meticillin-resistant Staphylococcus aureus among adults in community settings in Taiwan. J Clin Microbiol. 2009;47:2957–63.
35. Boyles-Vavra S, Ereshefsky B, Wang CC, Daum RS. Successful multiresistant community-associated meticillin-resistant Staphylococcus aureus. J Clin Microbiol. 2005;43:4719–30.